Intelligence Feed event · Equity · 2026-10-04

    DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/E

    Question

    DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/E

    Direct answer

    DaVita HealthCare is positioned for substantial operational earnings expansion ahead of its third-quarter financial release. Consensus projections call for earnings per share of $3.78, reflecting a 50.6% year-over-year increase in operating profitability. The dialysis provider's valuation multiple sits at 12.1 times forward earnings, reflecting a discount to the broader healthcare facilities sector median of 19.68x, offering defensive cash flow exposure in an elevated rate environment.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/E”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/davita-projects-q3-eps-of-3-78-with-50-6-yoy-growth-trading-at-12-1x-forward-p-e-143f96

    EQUITY
    DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/E
    DaVita HealthCare is positioned for substantial operational earnings expansion ahead of its third-quarter financial release. Consensus projections call for earnings per share of $3.78, reflecting a 50.6% year-over-year increase in operating profitability. The dialysis provider's valuation multiple sits at 12.1 times forward earnings, reflecting a discount to the broader healthcare facilities sector median of 19.68x, offering defensive cash flow exposure in an elevated rate environment.
    DVA
    Impact
    63
    OCT 4
    SIG
    85%
    DVA
    DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/E
    DaVita HealthCare is positioned for substantial operational earnings expansion ahead of its third-quarter financial release. Consensus projections call for earnings per share of $3.78, reflecting a 50.6% year-over-year increase in operating profitability. The dialysis provider's valuation multiple sits at 12.1 times forward earnings, reflecting a discount to the broader healthcare facilities sector median of 19.68x, offering defensive cash flow exposure in an elevated rate environment.
    → Outsized EPS expansion of 50.6% against a discounted forward P/E multiple of 12.1x drives multiple re-rating potential in defensive healthcare service providers.
    Impact
    DaVita HealthCare is positioned for substantial operational earnings expansion ahead of its third-quarter financial release. Consensus projections call for earnings per share of $3.78, reflecting a 50.6% year-over-year increase in operating profitability. The dialysis provider's valuation multiple sits at 12.1 times forward earnings, reflecting a discount to the broader healthcare facilities sector median of 19.68x, offering defensive cash flow exposure in an elevated rate environment.
    Affected
    DVA
    Transmission
    Outsized EPS expansion of 50.6% against a discounted forward P/E multiple of 12.1x drives multiple re-rating potential in defensive healthcare service providers.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    DVAoperating leverage driving 50.6% EPS growth on discounted multipleUp1-4wDaVita projected EPS of $3.78 representing 50.6% YoY growth at 12.1 forward P/E.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month